Biotech Values

[RockRat]

If the safety is better, and the cost lower (should be), the drug could indeed have a potential role. I could see a treatment regimen in which a patient is started with Lucentis, then given Bevasiranib, or perhaps both at once. It will take more studies than Acuity would hope, though.

I agree there is a fair amount of spin in that PR.

Regards, RockRat